Chronische Entzündungserkrankungen in Deutschland: Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Jan Leipe - , Sektion Rheumatologie (Autor:in)
  • Renate Schmelz - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, ENGINE Deutschland (Autor:in)
  • Gabriela Riemekasten - , Universitätsklinikum Schleswig-Holstein Campus Lübeck (Autor:in)
  • Diamant Thaçi - , Universität zu Lübeck (Autor:in)
  • Jörg Henes - , Universitätsklinikum Tübingen (Autor:in)
  • Knut Schäkel - , Universitätsklinikum Gießen und Marburg GmbH (Autor:in)
  • Andreas Pinter - , Universitätsklinikum Frankfurt (Autor:in)
  • Michael Sticherling - , Universitätsklinikum Gießen und Marburg GmbH (Autor:in)
  • Joanna Wegner - , Universitätsmedizin Mainz (Autor:in)
  • Stefano Fusco - , Medizinische Klinik und Poliklinik I (Autor:in)
  • Miriam Linke - , Universitätsmedizin Mannheim (Autor:in)
  • Valeria Weber - , IGES Institut GmbH (Autor:in)
  • Karina C Manz - , IGES Institut GmbH (Autor:in)
  • Holger Bartz - , Janssen Pharmaceutica NV (Autor:in)
  • Marit Roecken - , Janssen Pharmaceutica NV (Autor:in)
  • Sandra Schmidt - , Janssen Pharmaceutica NV (Autor:in)
  • Bimba F Hoyer - , Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)

Abstract

BACKGROUND: Immune-mediated inflammatory diseases (IMID) can lead to a substantial disease burden for those affected, in particular by the concomitant occurrence of other IMIDs or in the presence of comorbidities. The care of patients with IMIDs is complex and involves various medical disciplines.

OBJECTIVE: To describe the burden of disease and the current routine drug treatment of patients with IMID.

MATERIAL AND METHODS: The retrospective cross-sectional analysis was based on statutory health insurance claims data from the InGef database. Prevalent patients with psoriasis (Pso), psoriatic arthritis (PsA), spondylarthritis (SpA), rheumatoid arthritis (RA), Crohn's disease (MC), ulcerative colitis (CU), or connective tissue disease were identified among 3,988,695 insured patients in 2018. The concomitant occurrence of different IMIDs and the extent to which patients with IMID are affected by other comorbidities compared to a reference population were investigated. The current routine drug treatment was described based on the use of predefined forms of treatment.

RESULTS: In the database 188,440 patients with IMID (4.7%) were identified. Compared to the reference population the prevalence of comorbidities, such as depressive episodes and cardiovascular risk factors was higher in patients with IMID. For MC, CU, RA, and PsA disease-modifying antirheumatic drugs (DMARD) and classical systemic forms of treatment were used most commonly. In Pso, SpA, and connective tissue disease nonsteroidal anti-inflammatory drugs (NSAID) were the most frequently used treatment often in combination with other drugs.

CONCLUSION: A considerable number of patients with IMIDs (16.9-27.5%) suffer from different diseases of the IMID group. They are frequently affected by accompanying illnesses and require interdisciplinary medical treatment.

Details

OriginalspracheDeutsch
Seiten (von - bis)200-209
Seitenumfang10
FachzeitschriftZeitschrift fur Rheumatologie
Jahrgang83
Ausgabenummer3
PublikationsstatusElektronische Veröffentlichung vor Drucklegung - 4 Jan. 2023
Peer-Review-StatusJa

Externe IDs

Scopus 85145586293
Mendeley 055daa0e-a4da-3de7-b8b6-4fcd1c313e74

Schlagworte

ASJC Scopus Sachgebiete

Schlagwörter

  • Chronic inflammatory diseases, Epidemiology, Pharmacotherapy, Real-world evidence, Statutory health insurance data analysis